Vaxcyte — Business Overview

What does Vaxcyte do?

Vaxcyte is a clinical-stage vaccine company with no approved products yet, working to develop a new generation of bacterial vaccines. It is not yet generating product revenue. Instead, it is spending money to advance its pipeline through clinical trials, with the goal of eventually winning FDA approval and commercializing its vaccines.

The company's pipeline centers on pneumococcal conjugate vaccines (PCVs) — shots that protect against Streptococcus pneumoniae, the bacteria behind diseases like meningitis, pneumonia, and "strep ear." Its lead candidate, VAX-31, is a 31-valent PCV (meaning it targets 31 bacterial strains), designed to be broader-spectrum than any pneumococcal vaccine currently on the market. Secondary pipeline assets include VAX-24 (a 24-valent PCV for infants), VAX-XL (an even broader next-generation candidate, still preclinical), and VAX-A1 (a novel Group A Strep vaccine heading into Phase 1 trials in 2026). A fourth program targeting Shigella (VAX-GI) has been paused to conserve resources. Vaxcyte had 507 full-time employees as of December 31, 2025.

How does Vaxcyte make money?

Vaxcyte currently does not make money from product sales — it is pre-revenue in the traditional sense. As a clinical-stage company, its cash outlays fund R&D and manufacturing buildout. Future revenue would come from selling approved vaccines directly into the commercial market, without a licensing or partnership model disclosed as a primary monetization route.

If VAX-31 gains FDA approval for adults (the nearest-term commercial event), Vaxcyte would target the U.S. adult pneumococcal vaccine market, which generated more than $1.5 billion in estimated annual sales in 2025. The company has already committed to a long-term commercial manufacturing deal with Thermo Fisher Scientific for fill-finish services at its Greenville, North Carolina facility, worth up to $1 billion over the life of the agreement, and a dedicated drug substance manufacturing suite being built by Lonza in Visp, Switzerland. It also owes Sutro Biopharma a 4% royalty on net sales of human vaccines once products are commercialized.

What market does Vaxcyte operate in?

The global vaccine market is large and growing, projected to reach $115.77 billion by 2033 from $72.75 billion in 2025, a compound annual growth rate of roughly 5.8%. Vaccines are considered one of the most durable categories in healthcare — demand is driven by annual birth cohorts for pediatric programs and expanding age recommendations for adults. In October 2024, the ACIP lowered the recommended age for pneumococcal vaccination in adults from 65 to 50, adding approximately 62 million newly eligible Americans overnight.

Vaxcyte's primary target is the global pneumococcal vaccine market, estimated at approximately $8 billion. This market is well-established and growing, with leading products from Pfizer, Merck, and GSK generating a combined $8.5 billion in global pneumococcal vaccine sales in 2025. A key tailwind is the phenomenon of "serotype replacement" — as existing vaccines suppress certain bacterial strains, other strains fill the void, creating a recurring need for broader-spectrum vaccines. This dynamic has driven iterative product generations (from 7-valent to 13-, 15-, 20-, and 21-valent vaccines) and is expected to continue favoring companies that can expand coverage.

The adult vaccine market represents a newer and faster-growing opportunity. Historically focused on children, vaccine manufacturers are now developing more products for adults. The adult pneumococcal market alone topped $1.5 billion in the U.S. in 2025, and other adult vaccines like GSK's Shingrix (shingles) reached $4.8 billion in global sales. Policy changes, aging demographics, and growing awareness of vaccine-preventable disease in adults are secular tailwinds.

Who are Vaxcyte's main competitors?

The pneumococcal vaccine market is highly concentrated among a handful of large pharmaceutical companies, with Pfizer dominant at approximately 77% of the roughly $8.5 billion in global pneumococcal sales in 2025. Merck holds about 21% and GSK about 2%. These are the companies Vaxcyte would need to displace.

Vaxcyte's claimed competitive advantage is its XpressCF cell-free protein synthesis platform, which enables "site-specific conjugation." Conventional vaccines attach polysaccharide antigens to a protein carrier randomly, which can block immune-stimulating regions on the carrier — a problem called "carrier suppression" that limits how many strains can be packed into one shot without sacrificing immune response. Vaxcyte's method attaches antigens at pre-selected points, preserving those regions and allowing a broader-spectrum vaccine with less carrier protein. The company argues this is why VAX-31 at 31 strains can outperform conventional 20- or 21-valent vaccines immunologically.

The FDA's November 2024 Breakthrough Therapy Designation for VAX-31 — covering both IPD and pneumonia prevention in adults — is a meaningful marker. This designation signals the FDA believes preliminary evidence suggests VAX-31 may offer substantial improvement over existing therapies and accelerates the development and review process.

Where does Vaxcyte operate?

Vaxcyte is headquartered in San Carlos, California, and its clinical trials are conducted primarily in the United States. Phase 3 adult trials (OPUS-1, OPUS-2, and OPUS-3) are enrolling participants across approximately 50, 25, and 30 U.S. sites, respectively. The infant Phase 2 study for VAX-31 does not specify sites as non-U.S. in the filing.

Vaxcyte does not own any manufacturing facilities and relies entirely on contract manufacturers, with key production infrastructure located internationally. Its primary drug substance manufacturer, Lonza, is constructing a dedicated commercial suite in Visp, Switzerland. Final drug product (fill-finish) will be manufactured domestically at Thermo Fisher's Greenville, North Carolina facility under a 15-year commercial agreement. This split creates some geographic supply chain dependency on a single Swiss site for upstream manufacturing.

The company holds patent applications internationally across more than a dozen countries and regions — including China, Japan, South Korea, Australia, India, Canada, Brazil, and within the European Patent Convention — signaling an intent to pursue global commercial rights, though no international commercial partnerships are disclosed at this stage.